Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ADPT
ADAPTIVE BIOTECHNOLOGIES CORPORATION
NASDAQ
$25.19
▼ DOWN 4.73% (-1.25)

KEY STATISTICS

Market Cap$4.03 B
52w High$26.87
52w Low$12.00
Dividend Yield—
Frequency—
P/E-61.44
Volume1.51M
Shares Out.160.04M

COMPANY

LEADERSHIP

Chad Robins
CHIEF EXECUTIVE
Chad Robins

COMPENSATION 2026

Salary$698,258
Stock Awards$7,675,100
Incentive Plan Pay$703,380
All Other Comp.$4,952
Total$9,081,690

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 27, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
624

PRICE TARGET

Target High$27.50
Target Low$20.00
Target Median$25.00
Target Consensus$24.38

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$71.65M
NOV
4
WED

SPLIT RECORD

DATETYPERATIO
2026-07-15Reverse1:4

PRICE

$25.19 ▼ DOWN 4.73% (−$1.25)
OVERLAYS
$25.50$26.00$26.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM25.19

About Adaptive Biotechnologies Corporation

https://www.adaptivebiotech.com ↗

Adaptive Biotechnologies develops immune-based diagnostic and therapeutic platforms, including immunoSEQ and clonoSEQ, for disease detection, monitoring, and treatment across cancer, autoimmune, and infectious diseases.

INDUSTRY

Biotechnology

A PRODUCT ADAPTIVE BIOTECHNOLOGIES CORPORATION IS KNOWN FOR

clonoSEQ®
clonoSEQ®

clonoSEQ® is an FDA-cleared NGS-based diagnostic test that detects and monitors minimal residual disease in blood cancers, aiding treatment assessment, predicting outcomes, and early relapse detection, fueling Adaptive Biotechnologies' revenue gro...

COMPETITORS

COMPETITOR
GH COMPARE
NEO COMPARE
NTRA COMPARE
PSNL COMPARE

Revenue by Products

IconPRODUCTQ1-2021Q2-2021Q3-2021Q4-2021
Development Revenue$23.27M — — —
Sequencing Revenue$15.17M — — —
Medicare Revenue— $500K $1.4M ▲$500K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
166
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.00% · 4.9M
XSU.TO
0.12% · 3.9M
ARKG
2.34% · 1.9M
FESM
0.29% · 735.9K
SCHA
0.07% · 586.0K
FYC
0.65% · 354.2K
ZPRR.DE
0.13% · 289.0K
DOCG.L
2.19% · 272.4K
PSC
0.21% · 224.9K
BR
BRES
0.62% · 170.2K
XRS2.F
0.13% · 141.2K
DWAS
0.83% · 136.3K
TMAT
1.15% · 120.2K
RSSL
0.13% · 73.6K
GSSC
0.17% · 71.9K
HTEC
2.19% · 64.6K
FFTY
1.95% · 57.8K
HELX
4.51% · 55.7K
SILX
1.89% · 46.2K
BBSC
0.16% · 44.5K
ETHO
0.53% · 40.8K
MEDI
1.08% · 17.9K
ACSG
0.67% · 13.1K
AI
AIMS
0.34% · 11.9K
TILT
0.01% · 9.6K
WELL.L
1.22% · 7.1K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
66.33%
HOLDERS
423
TOP 12 OF 423 · RANKED BY POSITION SIZE
Viking Global Investors LP
30.0M sh · $643.37M
Blackrock, Inc.
15.1M sh · $324.73M
Blackrock Inc.
11.7M sh · $42.22M
Vanguard Group Inc
11.3M sh · $183.22M
Ameriprise Financial Inc
6.0M sh · $89.34M
Wellington Management Group Llp
5.9M sh · $126.8M
Westfield Capital Management Co LP
5.4M sh · $75.46M
D. E. Shaw & Co., Inc.
4.6M sh · $99.22M
Invesco Ltd.
4.5M sh · $61.77M
Price T Rowe Associates Inc /Md/
4.4M sh · $71.25M
Nikko Asset Management Americas, Inc.
3.7M sh · $54.65M
Sumitomo Mitsui Trust Holdings, Inc.
3.7M sh · $54.61M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

TRADES BY CONGRESS

HOUSE TRADES
Ro Khanna
Ro Khanna
Purchase
2022-02-14

INSIDER TRADES

★
DIRECTOR
OWEN KATEY EINTERZ
Sale · 9.6K shares
2026-08-26
★
DIRECTOR
HERSHBERG ROBERT
Sale · 15.7K shares
2026-08-18
★
DIRECTOR
HERSHBERG ROBERT
Sale · 15.0K shares
2026-08-18
★
DIRECTOR
HERSHBERG ROBERT
Purchase · 15.0K shares
2026-08-18

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OVERWEIGHT 2
EQUAL WEIGHT 1
6 GRADES IN THE LAST 12 MONTHS
Piper Sandler OVERWEIGHT Guggenheim BUY TD Cowen BUY Morgan Stanley EQUAL WEIGHT BTIG BUY JP Morgan OVERWEIGHT

SECTORS PEERS

PEERPRICE
SRRK$57.80COMPARE
IDYA$40.11COMPARE
LEGN$19.88COMPARE
TARS$71.76COMPARE
IRON$80.03COMPARE
BEAM$29.32COMPARE
ZLAB$26.08COMPARE
MLYS$25.60COMPARE